| Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. | |
| | |
MedLine Citation:
|
PMID: 20199195 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT AND OBJECTIVE: Insulin glargine (Lantus) stimulates growth of MCF-7 cells stronger than human insulin. We investigated if serum from diabetic patients treated with glargine versus human insulin may display a similar effect. METHODS: Pairs of serum samples from 31 C-peptide negative type-1 diabetic patients were investigated. In cross-over fashion, 23 patients were treated with glargine plus rapid-acting insulin analogues, and similar doses of human NPH and rapid-acting insulin. For comparison, eight patients were treated with insulin detemir (Levemir) and human NPH. MCF-7 cells were incubated with 10% serum and proliferation was assessed after 72 hours. RESULTS: Serum containing insulin glargine was 1.11(95% CI 1.05-1.18) fold more mitogenic than human insulin-containing serum (p < 0.005); mitogenicity of serum containing detemir was 0.99(95% CI 0.98-1.02) fold that of human insulin-containing serum. CONCLUSION: The serum of diabetic patients was slightly stronger mitogenic when using glargine as compared to human insulin or detemir for treatment. |
| | |
Authors:
|
Doris Mayer; Ernst Chantelau |
Related Documents
:
|
19667675 - Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia. 1149305 - Hypoglycaemia associated with an intrathoracic fibrosarcoma. 20636965 - Similarity of pharmacodynamic effects of a single injection of insulin glargine, insuli... 1851695 - Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorh... 7433515 - Range-related glycaemic response to increasing load of carbohydrates. 18443035 - Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amin... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Archives of physiology and biochemistry Volume: 116 ISSN: 1744-4160 ISO Abbreviation: Arch. Physiol. Biochem. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-27 Completed Date: 2010-07-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9510153 Medline TA: Arch Physiol Biochem Country: England |
Other Details:
|
Languages: eng Pagination: 73-8 Citation Subset: IM |
Affiliation:
|
Hormones and Signal Transduction Group, German Cancer Research Centre, DKFZ-ZMBH Alliance, Im Neuenheimer Feld 581, Heidelberg, Germany. d.mayer@dkfz.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Breast Neoplasms
/
chemically induced,
drug therapy C-Peptide / therapeutic use Cell Line, Tumor Cells Chemotactic Factors / therapeutic use Diabetes Mellitus / chemically induced, drug therapy* Diabetes Mellitus, Type 1 / blood, chemically induced, drug therapy* Female Humans Insulin / adverse effects, analogs & derivatives*, therapeutic use* Pilot Projects Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/C-Peptide; 0/Chemotactic Factors; 0/glargine; 0/insulin detemir; 11061-68-0/Insulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Finite element analysis of controlled cortical impact-induced cell loss.
Next Document: Symphysiolysis as an independent risk factor for cesarean delivery.